Ride to Care - A Pilot Study to Investigate the Clinical and Quality of Life Benefit of Eliminating Transportation Barriers for Disadvantaged Cancer Patients Undergoing Ambulatory Palliative Radiotherapy
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 主要终点
- Rate of unplanned hospital admissions
研究概览
简要总结
This trial studies how well Uber health intervention works in eliminating transportation barriers for disadvantaged patients with cancer that has spread to nearby tissue, lymph nodes, or other places in the body, undergoing ambulatory palliative radiotherapy. Uber health intervention provides free transportation to disadvantaged patients and may reduce the amount of missed radiotherapy appointments, patient anxiety, and the amount of unplanned emergency department visits, as well as improve quality of life.
详细描述
PRIMARY OBJECTIVES:
I. To test whether eliminating transportation barriers for disadvantaged cancer patients can reduce the 6-month rate of unplanned emergency department (ED) visits.
SECONDARY OBJECTIVES:
I. To test whether eliminating transportation barriers for disadvantaged cancer patients for the duration of a palliative radiotherapy course will improve prescribed treatment completion rates and reduce treatment delays and overall time to treatment completion.
II. To test whether eliminating transportation barriers for disadvantaged cancer patients for the duration of a palliative radiotherapy course will have an impact on physician choice for therapeutic modality, [3-dimensional conformal radiation therapy (3D CRT) versus intensity-modulated radiation therapy (IMRT) versus stereotactic body radiation therapy (SBRT)] and the fractionation schedules to minimize patient inconvenience.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Health Services Research
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent (and assent when applicable) obtained from patient or patients's legal representative and ability for patient to comply with the requirements of the study
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- •Histologically confirmed locally advanced or metastatic cancer
- •Patients who have received prior courses of radiotherapy are eligible
- •If patient answers yes to >= 1/4 of the questions below:
- •In the last six months, have you ever delayed seeing a doctor or getting care?
- •Do you anticipate having a hard time coming to University of California, San Francisco (UCSF) for radiation therapy due to transportation challenges?
- •Does lack of money for transportation expenses (parking, taxi, bus) make it difficult for you to get care quickly for medical problems?
- •Does arranging for transportation (driving yourself, getting neighbor or family to drive you) for your cancer treatments make you anxious or worried?"
排除标准
- •Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study
- •Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data
- •Patients who are living at a facility such as a nursing home or skilled nursing facility
- •Patients who do not live within a 30-mile radius of one of the radiation oncology sites at University of California San Francisco (UCSF)
- •Patients who are currently receiving or expected to be receive UCSF affiliated transportation services prior to enrollment onto the study
结局指标
主要结局
Rate of unplanned hospital admissions
时间窗: Up to 6 months
For each enrolled patient, any unplanned hospital admission the six months from consultation/enrollment will be documented as an event.
Rate of unplanned emergency department (ED) visits
时间窗: Up to 6 months
For each enrolled patient, any unplanned ED visit over the six months from consultation/enrollment will be documented as an event.
次要结局
- Change in functional domain scores on the EORTC-QLQ-C30(Up to 3 years)
- Percentage of participants who completed total treatment(Up to 3 years)
- Number of participants with grade >= 3 acute radiation related adverse events(Up to 3 years)
- Median days of treatment delays(Up to 3 years)
- Number of participants with grade >= 3 chronic radiation related adverse events(Up to 3 years)
- Overall survival (OS)(Up to 3 years)
- Change in mean pain score on the European Organization for Research and Treatment of Cancer quality of life questionnaire 30 (EORTC-QLQ-C30)(Up to 3 years)
- Change in mean overall global health status score on the EORTC-QLQ-C30(Up to 3 years)
- Number of participants with a reported treatment delay(Up to 3 years)
- Percentage of participant requiring re-treatment(Up to 3 years)